Diabetes News

The Cardiometabolic Health Congress announced that Peter Libby, MD, one of the foremost authorities in atherosclerosis, will deliver the keynote address at its upcoming 19th annual conference.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.

Adults with prediabetes and overweight or obesity who take the GIP/GLP-1 dual agonist tirzepatide once weekly may be 94% less likely to develop type 2 diabetes, according to results from the SURMOUNT-1 study.

Primary care practices can successfully implement continuous glucose monitoring for patients with diabetes by using American Academy of Family Physicians resources or a virtual CGM initiation service, according to two speakers.

Asian American, Native Hawaiian and Pacific Islander, or AA and NH/PI, communities continue to face significant racial disparities in health care access and outcomes across the United States, according to an expert.

SGLT2 inhibitors and dulaglutide confer a similar risk for dementia among adults aged 60 years and older with type 2 diabetes, according to findings published in Annals of Internal Medicine.

High BMI eligibility for semaglutide could cost Medicare up to $145 billion annually, a brief report published in the Annals of Internal Medicine revealed.

Adults who take semaglutide may have increased risk for developing suicidal thoughts, according to results from a case-control study published in JAMA Network Open.